Progyny Inc
NASDAQ:PGNY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.67
41.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Progyny Inc
Progyny Inc
Cost of Revenue
Progyny Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Progyny Inc
NASDAQ:PGNY
|
Cost of Revenue
-$891.9m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
UnitedHealth Group Inc
NYSE:UNH
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centene Corp
NYSE:CNC
|
Cost of Revenue
-$145B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Molina Healthcare Inc
NYSE:MOH
|
Cost of Revenue
-$32.9B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-16%
|
|
|
Humana Inc
NYSE:HUM
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Elevance Health Inc
NYSE:ELV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Progyny Inc
Glance View
Progyny, Inc. is a fertility benefits management company. The company is headquartered in New York City, New York and currently employs 311 full-time employees. The company went IPO on 2019-10-25. The firm specializes in fertility and family building benefits solutions in the United States. The firm provides its benefit through its Smart Cycle approach. The Smart Cycle includes medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition, to its fertility benefits solution, it offers an integrated pharmacy benefits solution, Progyny Rx, which is added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. As part of this solution, the Company provide care management services, which include its formulary plan design, simplified authorization, assistance with prescription fulfillment and timely delivery of the medications by its network of specialty pharmacies, as well as medication administration training, pharmacy support services and patient care advocates.
See Also
What is Progyny Inc's Cost of Revenue?
Cost of Revenue
-891.9m
USD
Based on the financial report for Sep 30, 2024, Progyny Inc's Cost of Revenue amounts to -891.9m USD.
What is Progyny Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-42%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for Progyny Inc have been -35% over the past three years , -42% over the past five years .
You don't have any saved screeners yet
